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terms of morbidity and mortality, implying considerable
healthcare costs and loss of productivity, there is a lack
of data about the economic impact of an influenza epi-
demic in Italy. OBJECTIVES: The aim of this study was
to estimate the social cost of a normal influenza epidemic
in Italy using a generic algorithm for influenza outbreak
and treatment. METHODS: Referring to the demo-
graphic characteristics of the population, to the pub-
lished literature and to the epidemiological data (influ-
enza season 1998/99), a simulation of the impact of a
real influenza epidemic was run. The health service use
and unit costs were estimated from standard data
sources. RESULTS: The average direct costs of influenza
per person in Italy were lit. 68,000 ($US 36) for the over-
all population, and lit. 155,000 ($_S 82.26) for a high-
risk patient; the average indirect costs of influenza per
working patient were lit. 569,000 ($US 301.97). Hence,
the total cost of a case of influenza in Italy was about lit.
637,000 ($US 338). In general, around 90% of total
costs consisted of indirect costs. Costs are sensitive to
changes in the rate of hospitalization and to changes in
the proportion of the active population. CONCLU-
SIONS: Cost-of-illness studies should be “observational”
to reflect the real world. Nevertheless, if relevant data are
not available, a suitable model which uses reliable data
can give consistent estimates of the cost of influenza in It-
aly. This kind of model may help decision-makers
heighten awareness of the burden of influenza and design
prevention and treatment strategies.
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US estimates show that 1.7 million annually develop
pressure ulcers incurring costs of $8.5 billion. Leg ulcers
affect 2.5 million persons in the US and their prevalence
will likely rise as the population ages. OBJECTIVES: We
determined the average costs and frequencies of prescrip-
tion, physician and inpatient hospital claims for four di-
agnostic categories of skin ulcers from 1994 through
1998, including ulcers of lower limbs (ICD-9 code
707.1), pressure ulcers (ICD-9 code 707.0), venous leg
ulcers (ICD-9 codes 454.0/454.2) and other chronic ul-
cers (ICD-9 codes 707.8/707.9). METHODS: A retro-
spective review of the New Mexico Medicaid (NMM)
Drug Utilization Review (DUR) database was conducted.
Data on frequency of hospital admissions, physician vis-
its, and medications, as well as related costs, were ana-
lyzed. Prescription claims were not specific to ulcers, and
included the top ten concomitant drugs. RESULTS:
Mean annual hospital costs per patient ranged from
$8671.48 (SD  $444.10) for other chronic ulcers to
$15,733.16 (SD  $482.14) for venous leg ulcers. Mean
annual hospital admissions per patient ranged from 1.25
(SD  0.02) for other chronic ulcer to 1.50 (SD  0.06)
for venous leg ulcers. Mean annual physician costs per
patient ranged from $111.09 (SD  $14.16) for other
chronic ulcers to $196.08 (SD  $20.64) for ulcers of the
lower limbs. Mean annual physician visits per patient
ranged from 2.05 (SD  0.16) for other chronic ulcers to
3.63 (SD  0.32) for ulcers of the lower limb. Mean an-
nual prescription cost per patient was $4179.18 (2461
patients). CONCLUSIONS: Costs from the perspective
of the NMM program are substantial. Assessment of the
cost-effectiveness of various treatments is warranted.
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Antibiotic treatment of respiratory tract infection (RTI)
has been evaluated in many clinical trials, but little is
known about its effectiveness (efficacy in real life condi-
tions) and costs. OBJECTIVE: To measure the effective-
ness, side effects and costs associated with the use of var-
ious antibiotics in the ambulatory treatment of RTI in
adults. METHODS: Patients aged 18 were recruited by
community pharmacists. They were considered for inclu-
sion if they reported being treated for an RTI and re-
ceived a new prescription for one of the following antibi-
otics: amoxicillin, amoxicillin/clavulanate, azithromycin,
cefaclor, cefuroxime, ciprofloxacin, clarithromycin or
erythromycin. Presence of symptoms, side effects and re-
source utilization were reported in a self-administered
questionnaire covering the first 14 days after treatment
was initiated. A follow-up call at 28 days completed the
data collection. Resource utilization considered included
initial antibiotic, physician and pharmacist services, other
medications (prescribed and OTC), and alternate antibi-
otic when required. RESULTS: Of 989 patients recruited,
777 returned their questionnaire (79%). At day 7, 33%
of patients reported having symptoms. This proportion
did not vary according to the antibiotic even when con-
trolling for the type of RTI (URTI vs. LRTI) (2, P 
0.05). Diarrhea was reported by 17%, nausea by 11%
and abdominal pain by 10% of patients. Erythromycin
had the largest proportion of patients reporting a GI side
effect (53%). Average cost per episode varied between
$34 and $89 (Canadian). Lower costs were seen for pa-
tients started with amoxicillin or erythromycin. The
highest cost was seen in patients started with cefaclor/
cefuroxime. CONCLUSION: Effectiveness was not de-
pendent on the antibiotic selected at the start of treat-
ment. Occurrence of side effects was relatively high.
